Several clinical trials have indicated that CD19 CAR T-cell therapy could induce HLH/MAS (99), and a recent CD22 CAR T-cell clinical trial also reported a 38% incidence of HLH/MAS-like toxicities at an average time of 14 days after infusion (14). Here, CD19 is linked to hemophagocytic syndrome.